Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase I/IIa PAL-222 in refractory skin ulcers
jRCT2053240282Phase 1Recruiting
- Sponsor
- Pharmbio Korea Inc.
- Start
- May 2025
- Modality
- Stem Cell Therapies → Cell Therapies
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of PAL-222 in Cutaneous ulcer, sponsored by Pharmbio Korea Inc. Primary endpoints: Safety: adverse events and device malfunctions, Safety: changes in clinical laboratory test values and 1 more. Started May 2025; status: recruiting.
02
Drugs
PAL-222
03
Conditions
Cutaneous ulcer
Beyond the preview
Go deeper on jRCT2053240282.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2053240282.